Company:  INFINITY PHARMACEUTICALS, ... (INFI)
Form Type:  10-Q
Filing Date:  5/7/2013 
CIK:  0001113148 
Address:  780 MEMORIAL DRIVE 
City, State, Zip:  CAMBRIDGE, Massachusetts 02139 
Telephone:  (617) 453-1000 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$9.94  
Change: 
-0.03 (-0.30%)  
Trade Time: 
04:00 PM EST  
Market Cap: 
$479.91M
Description of Business
We are an innovative biopharmaceutical company dedicated to discovering, developing and delivering best-in-class medicines to people with difficult-to-treat diseases. We combine proven scientific expertise with a passion for developing novel small molecule drugs that target emerging disease pathways. We have worldwide development and commercialization rights to all of our development candidates and early discovery programs, subject to certain financial obligations to our current licensor and former development partners. IPI-145, our lead product candidate, is a potent, oral inhibitor of Class I delta and gamma isoforms of phosphoinositide-3-kinase, or PI3K, which we are investigating in both hematologic malignancies and inflammatory diseases. The PI3Ks are a family of enzymes involved in multiple cellular functions, including cell proliferation and survival, cell differentiation, cell migration and immunity.
Register for EDGAR Pro and access this filing in:     
  FORM 10-Q
    PART I. FINANCIAL INFORMATION
      Item 1. Unaudited Condensed Consolidated Financial Statements
        BALANCE SHEET
        INCOME STATEMENT
        CASH FLOW
        Notes to Condensed Consolidated Financial Statements
      Item 2. Management's Discussion and Analysis of Financial ...
      Item 3. Quantitative and Qualitative Disclosures About ...
      Item 4. Controls and Procedures
    PART II. OTHER INFORMATION
      Item 1A. Risk Factors
      Item 6. Exhibits
    SIGNATURES
    EXHIBIT INDEX
  EXHIBIT 31.1
    CERTIFICATION PURSUANT TO RULES 13A-14(A) AND 15D-14(A)
  EXHIBIT 31.2
    CERTIFICATION PURSUANT TO RULES 13A-14(A) AND 15D-14(A)
  EXHIBIT 32.1
  EXHIBIT 32.2
BROKERAGE PARTNERS